Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

References

• Crawford MP, Yan SX, Ortega SB et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood103, 4222–4231 (2004).
   PubMed Web of Science ®Google Scholar
• Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med.184, 771–775 (1996).
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med.201, 233–240 (2005).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med.181, 381–386 (1995).
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Koh CS, Inoue A et al. Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing–remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J. Neuroimmunol.102, 56–66 (2000).
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Wysocka M, Hilliard B et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J. Immunol.161, 5097–5104 (1998).
   PubMed Web of Science ®Google Scholar
• ‘tHart BA, Brok HP, Remarque E et al. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J. Immunol.175, 4761–4768 (2005).
   PubMed Web of Science ®Google Scholar
• Brok HP, Van Meurs M, Blezer E et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J. Immunol.169, 6554–6563 (2002).
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol.7, 796–804 (2008).
   PubMed Web of Science ®Google Scholar
• Deshpande P, King IL, Segal BM. IL-12 driven upregulation of P-selectin ligand on myelin-specific T cells is a critical step in an animal model of autoimmune demyelination. J. Neuroimmunol.173, 35–44 (2006).
   PubMed Web of Science ®Google Scholar
• Bagaeva LV, Williams LP, Segal BM. IL-12 dependent/IFN γ independent expression of CCR5 by myelin-reactive T cells correlates with encephalitogenicity. J. Neuroimmunol.137, 109–116 (2003).
   PubMed Web of Science ®Google Scholar
• Kerfoot SM, Kubes P. Overlapping roles of P-selectin and α 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol.169, 1000–1006 (2002).
   PubMed Web of Science ®Google Scholar
• Karpus WJ, Lukacs NW, McRae BL et al. An important role for the chemokine macrophage inflammatory protein-1 α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol.155, 5003–5010 (1995).
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α 4 β 1 integrin. Nature356, 63–66 (1992).
   PubMed Web of Science ®Google Scholar
• Rice GP, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology64, 1336–1342 (2005).
   PubMed Web of Science ®Google Scholar
• Gran B, Zhang GX, Yu S et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol.169, 7104–7110 (2002).
   PubMed Web of Science ®Google Scholar
• Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med.187, 537–546 (1998).
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature421, 744–748 (2003).
   PubMed Web of Science ®Google Scholar
• Thakker P, Leach MW, Kuang W et al. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J. Immunol.178, 2589–2598 (2007).
   PubMed Web of Science ®Google Scholar
• Battistini L, Piccio L, Rossi B et al. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood101, 4775–4782 (2003).
   PubMed Web of Science ®Google Scholar
• van Veen T, Nielsen J, Berkhof J et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J. Neuroimmunol.190, 157–164 (2007).
   PubMed Web of Science ®Google Scholar
• Windhagen A, Newcombe J, Dangond F et al. Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med.182, 1985–1996 (1995).
   PubMed Web of Science ®Google Scholar
• Li Y, Chu N, Hu A et al. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain130, 490–501 (2007).
   PubMed Web of Science ®Google Scholar
• Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest.112, 1186–1191 (2003).
   PubMed Web of Science ®Google Scholar